TRP-2 / gp100 DNA vaccine and PD-1 checkpoint blockade combination for the treatment of intracranial tumors.

Autor: Pearson JRD; John Van Geest Cancer Research Centre, Nottingham Trent University, Nottingham, UK., Puig-Saenz C; John Van Geest Cancer Research Centre, Nottingham Trent University, Nottingham, UK., Thomas JE; John Van Geest Cancer Research Centre, Nottingham Trent University, Nottingham, UK., Hardowar LD; Department of Biosciences, School of Science and Technology, Nottingham Trent University, Nottingham, UK., Ahmad M; John Van Geest Cancer Research Centre, Nottingham Trent University, Nottingham, UK., Wainwright LC; Bioscience Support Facility, School of Science and Technology, Nottingham Trent University, Nottingham, UK., McVicar AM; Bioscience Support Facility, School of Science and Technology, Nottingham Trent University, Nottingham, UK., Brentville VA; Scancell Ltd, Unit 202, Bellhouse Building, Oxford Science Park, Sanders Road, Oxford, OX4 4GA, UK., Tinsley CJ; John Van Geest Cancer Research Centre, Nottingham Trent University, Nottingham, UK., Pockley AG; John Van Geest Cancer Research Centre, Nottingham Trent University, Nottingham, UK., Durrant LG; Scancell Ltd, Unit 202, Bellhouse Building, Oxford Science Park, Sanders Road, Oxford, OX4 4GA, UK., McArdle SEB; John Van Geest Cancer Research Centre, Nottingham Trent University, Nottingham, UK. stephanie.mcardle@ntu.ac.uk.

Publikováno v: Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2024 Jul 02; Vol. 73 (9), pp. 178. Date of Electronic Publication: 2024 Jul 02.